Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mezagitamab in adults with primary IgA nephropathy
NL-OMON59388Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Mezagitamab with Placebo (2 arms). Primary endpoint: Change from baseline in proteinuria at Week 36. Started Feb 2026; status: recruiting.
02
Drugs
mezagitamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON59388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59388.